Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents

Key Facts

Status: Open

Posted date: September 12, 2025

Opportunity ID: 360576

Opportunity number: PAR-26-049

Opportunity category: Discretionary

Agency name: National Institutes of Health

Agency code: HHS-NIH11

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
Category of Funding Activity
  • Health
Eligible Applicants
  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
  • Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities/Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_nih11
  • category_of_funding_activity:health
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:city_or_township_governments
  • eligible_applicants:county_governments
  • eligible_applicants:for_profit_organizations_other_than_small_businesses
  • eligible_applicants:independent_school_districts
  • eligible_applicants:native_american_tribal_governments_federally_recognized
  • eligible_applicants:native_american_tribal_organizations_other_than_federally_recognized_tribal_governments
  • eligible_applicants:nonprofits_having_a_501_c_3_status_with_the_irs_other_than_institutions_of_higher_education
  • eligible_applicants:nonprofits_that_do_not_have_a_501_c_3_status_with_the_irs_other_than_institutions_of_higher_education
  • eligible_applicants:others
  • eligible_applicants:private_institutions_of_higher_education
  • eligible_applicants:public_and_state_controlled_institutions_of_higher_education
  • eligible_applicants:public_housing_authoritiesindian_housing_authorities
  • eligible_applicants:small_businesses
  • eligible_applicants:special_district_governments
  • eligible_applicants:state_governments
  • funding_instrument_type:cooperative_agreement
  • opportunity_category:discretionary
  • status:open
Description

The National Institute of Mental Health (NIMH) seeks research that helps determine the best dosing strategies when testing new psychiatric medications in children and adolescents with serious mental illnesses.This NOFO will focus on developing and refining central nervous system (CNS) tools and models that can show how medications affect the brain in young people. These tools might include functional brain imaging methods like EEG or fMRI, as well as digital health measures or cognitive assessments. Studies are encouraged that explore how dosing impacts drug exposure (pharmacokinetics) and related CNS functional effects (pharmacodynamics). The overall goal is to improve the safety and effectiveness of pediatric clinical trials by developing pediatric pharmacodynamic measures, to associate pharmacodynamic data with pharmacokinetic data, and to establish associated models. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Researchers with expertise in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, clinical trials, or related fields are encouraged to consider applying to the new NOFO.

Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
The National Institute of Mental Health (NIMH) seeks research that helps determine the best dosing strategies when testing new psychiatric medications in children and adolescents with serious mental illnesses.This NOFO will focus on developing and refining central nervous system (CNS) tools and models that can show how medications affect the brain in young people. These tools might include functional brain imaging methods like EEG or fMRI, as well as digital health measures or cognitive assessments. Studies are encouraged that explore how dosing impacts drug exposure (pharmacokinetics) and related CNS functional effects (pharmacodynamics). The overall goal is to improve the safety and effectiveness of pediatric clinical trials by developing pediatric pharmacodynamic measures, to associate pharmacodynamic data with pharmacokinetic data, and to establish associated models. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Researchers with expertise in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, clinical trials, or related fields are encouraged to consider applying to the new NOFO.
Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
Open
National Institutes of Health
Health
Cooperative Agreement
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For-profit organizations other than small businesses
Small businesses
Others
2025-09-12